2025-01-08 IDOPRESS
BEIJING,Jan. 6,2025 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM),a healthcare provider specialized in cancer treatment,research,education and prevention in China,today announced that it held its 2024 annual general meeting of shareholders on December27,2024. At the meeting,the shareholders resolved by special resolution that amended and replaced the Fourth Memorandum and Articles of Association of the Company then in effect by the adoption of the Fifth Amended and Restated Memorandum and Articles of Association.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis,treatment,education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information,please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions,which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement,except as required under applicable law.
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Singapore Info Map